🟢 90/100

This product looks safe

  • Niacin: 600mg is 17.1× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 600mg is 17.1× the Tolerable Upper Intake Level (35mg)

Label Data

2 Capsule(s) Serving Size
30 Servings
Other Combinations Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

600 mg (3750% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 17.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 600mg UL 35mg
📊 Market median: 1000.0mg (223 products) 📚 11 studies (Tier A: 0, B: 5)
This product: 500mg
📊 Market median: 260.0mg (249 products) 📚 156 studies (Tier A: 4, B: 61)
This product: 25mg
📊 Market median: 100.0mg (283 products) 📚 142 studies (Tier A: 1, B: 64)
This product: 25mg UL 1200mg

Other Ingredients

Cellulose Cellulose Silica Rice Bran Extract

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Gluten Free Dairy Free

Product Information

📋 Directions for Use

Directions: Use only as directed. Take 2 capsules up to twice daily with food or as directed by your healthcare practitioner.

⚠️ Warnings & Precautions

Warning: Do not use if safety seal is broken or missing.

Keep your licensed healthcare practitioner informed when using this product, especially if pregnant or nursing.

This product is not to be used by anyone under 20 years of age.

🧪 Formulation Notes

Vegan

Non GMO Gluten free

BioLipotrol contains a blend of niacin, red yeast rice extract, CoQ10 and green tea leaf extract.

Additional Information

Innovative ingredients. Clinical formulations.

Keep tightly capped and store in a cool, dry place.

Product Details

UPC / SKU 8 12806 10212 9
DSLD Entry Date 2025-02-23
Product Type Other Combinations
Form Capsule
DSLD ID 322984
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →